ID Source | ID |
---|---|
PubMed CID | 441900 |
CHEMBL ID | 400807 |
CHEBI ID | 10086 |
SCHEMBL ID | 6040875 |
MeSH ID | M0503063 |
Synonym |
---|
nsc-226132 |
yamogenin |
C08918 |
512-06-1 |
CHEMBL400807 |
chebi:10086 , |
LMST01080045 |
(25s)-spirost-5-en-3beta-ol |
nsc 226132 |
spirost-5-en-3-ol, (3beta,25s)- |
neodiosgenin |
jamogenin |
unii-m487od4xw3 |
25-epi-diosgenin |
m487od4xw3 , |
S5675 |
(2r,5's)-5'-tetramethylspiro[[?]-2,2'-tetrahydropyran]ol |
SCHEMBL6040875 |
AKOS025402417 |
AC-8895 |
WQLVFSAGQJTQCK-CAKNJAFZSA-N |
(22r,25s)-(20.alpha.)-spirost-5-en-3.beta.-ol |
spirost-5-en-3-ol, (3.beta.,25s)- |
(20alpha,22r,25s)-spirosta-5-ene-3beta-ol |
(2'r,4s,5's,6ar,6bs,8as,8br,9s,11as,12as,12bs)-5',6a,8a,9-tetramethyl-1,3,3',4,4',5,5',6,6a,6b,6',7,8,8a,8b,9,11a,12,12a,12b-icosahydrospiro[naphtho[2',1':4,5]indeno[2,1-b]furan-10,2'-pyran]-4-ol |
HY-N2078 |
Q8048088 |
CS-0018583 |
DTXSID60903922 , |
(1s,2s,4s,5's,6r,7s,8r,9s,12s,13r,16s)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icos-18-ene-6,2'-oxane]-16-ol |
yamogenin - 70% |
XY165194 |
bdbm604165 |
us11660306, example yamogenin |
(22r,25s)-(20alpha)-spirost-5-en-3beta-ol |
dtxcid201331882 |
Yamogenin is a diastereomer of diosgenin, which we have identified as the compound responsible for the anti-hyperlipidemic effect of fenugreek.
Excerpt | Reference | Relevance |
---|---|---|
"Yamogenin is a diastereomer of diosgenin, which we have identified as the compound responsible for the anti-hyperlipidemic effect of fenugreek. " | ( Yamogenin in fenugreek inhibits lipid accumulation through the suppression of gene expression in fatty acid synthesis in hepatocytes. Goto, T; Hoshino, S; Kawada, T; Moriwaki, S; Murakami, H; Narukami, T; Takahashi, N; Taketani, K; Tsuge, N; Uemura, T, 2014) | 3.29 |
Class | Description |
---|---|
triterpenoid | Any terpenoid derived from a triterpene. The term includes compounds in which the C30 skeleton of the parent triterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups). |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID744419 | Cytotoxicity against human MDA-MB-231 cells | 2013 | Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9 | Spirostanoids with 1,4-dien-3-one or 3β,7α-diol-5,6-ene moieties from Solanum violaceum. |
AID744418 | Cytotoxicity against human A549 cells | 2013 | Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9 | Spirostanoids with 1,4-dien-3-one or 3β,7α-diol-5,6-ene moieties from Solanum violaceum. |
AID744421 | Cytotoxicity against human HepG2 cells | 2013 | Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9 | Spirostanoids with 1,4-dien-3-one or 3β,7α-diol-5,6-ene moieties from Solanum violaceum. |
AID744420 | Cytotoxicity against human MCF7 cells | 2013 | Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9 | Spirostanoids with 1,4-dien-3-one or 3β,7α-diol-5,6-ene moieties from Solanum violaceum. |
AID744422 | Cytotoxicity against human Hep3B cells | 2013 | Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9 | Spirostanoids with 1,4-dien-3-one or 3β,7α-diol-5,6-ene moieties from Solanum violaceum. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 7 (38.89) | 18.7374 |
1990's | 2 (11.11) | 18.2507 |
2000's | 3 (16.67) | 29.6817 |
2010's | 5 (27.78) | 24.3611 |
2020's | 1 (5.56) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (24.92) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 20 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |